methimazole and trimethylamine

Benzydamine (BZ), a weak base and an indazole derivative with analgesic and antipyretic properties used in human and veterinary medicine, is metabolized in human, rat, cattle and rabbit to a wide range of metabolites. One of the main metabolites, BZ N-oxide (BZ-NO), is produced in the liver and brain by flavin-containing monooxygenases (FMOs), by liver and brain enzymes. To evaluate the suitability of BZ as an FMO probe in veterinary species, BZ metabolism was studied in vitro using liver microsomes from bovine, rabbit and swine. Kinetic parameters, K(m) and V(max), of BZ-NO production, were evaluated to corroborate the pivotal role of FMOs. Inhibition studies were carried out by heat inactivation and by specific FMO chemical inhibitors: trimethylamine and methimazole. The results confirmed the presence of FMO activity in the liver and the role of BZ as a suitable marker of FMO enzyme activities for the veterinary species considered.

Topics: Animals; Anti-Inflammatory Agents; Benzydamine; Cattle; Chromatography, High Pressure Liquid; Female; Liver; Male; Methimazole; Methylamines; Microsomes, Liver; Oxygenases; Rabbits; Regression Analysis; Swine

To characterize the contribution of the human flavin-containing monooxygenase form 3 (FMO3) in the metabolism and disposition of drugs and xenobiotics, we determined the single nucleotide polymorphisms in the coding region and adjacent splice junctions of FMO3 in 134 African Americans and 120 Caucasians from the United States. In the regions examined, DNA resequencing or high throughput MassEXTEND studies coupled with mass spectrometric genotyping showed that 12 sites of variation were present. Three variants encoding synonymous mutations and four polymorphisms were observed in the noncoding region. Another three variants, Lys158-FMO3, Met257-FMO3 and Gly308-FMO3, previously reported in similar populations, were prominent polymorphisms. Two new polymorphisms, His132-FMO3 and Pro360-FMO3, were identified in this study. Both variants were found only in African Americans. To evaluate the effect of the amino acid substitutions on the function of FMO3, each amino acid substitution was introduced by site-directed mutagenesis into a wild-type FMO3 cDNA. Selective functional activity was studied with methimazole, trimethylamine, and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl) phenothiazine. Both His132-FMO3 and Pro360-FMO3 variants were able to metabolize the substrates examined. Compared with wild-type FMO3, the His132-FMO3 was less catalytically efficient. The His132-FMO3 variant moderately altered the catalytic efficiency of FMO3 (decrease of 30%, 60% and 6% with methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, respectively). The Pro360-FMO3 variant was more catalytically efficient than wild-type FMO3. Pro360-FMO3 oxygenated methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, respectively, 3-, 5- and 2-fold more efficiently than wild-type FMO3. Based on the functional activity of the variant FMO3 enzymes, it is likely that population differences exist for compounds primarily metabolized by FMO3.

Topics: Adult; Amino Acid Sequence; Black or African American; DNA; DNA, Complementary; Female; Gene Expression; Gene Frequency; Genetic Markers; Genotype; Humans; Male; Methimazole; Methylamines; Oxygenases; Phenothiazines; Phenotype; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; United States; White People

Five different members of the flavin-dependent monooxygenase gene family from different animal species have been described to date. We report the purification and characterization of two FMOs from sheep liver. The predominant isoform was purified 240-fold and was homogenous in SDS PAGE. Its molecular weight (MW) was 58 KDa. The N-terminal sequence, the cross-reactivity with anti-rat FMO3 antibodies, and the catalytic properties such the ability to metabolize trimethylamine (TMA) and to stereoselectively produce L-methionine-d-sulfoxide from L-methionine, are all consistent with this protein being an FMO3. The minor form has a MW of 59 KDa and cross-reacts with anti-rat FMO1 antibodies. The methimazole S-oxidase activity catalyzed by this form was not inhibited by TMA but was inhibited by imipramine. These facts imply that this protein is an FMO1. The expression profile of FMO in sheep liver is similar to that in the human or the mouse but differs from the rat profile.

Topics: Amino Acid Sequence; Animals; Binding Sites; Female; Gene Expression; Imipramine; Kinetics; Methimazole; Methionine; Methylamines; Microsomes, Liver; Molecular Sequence Data; Oxygenases; Sheep